Idioma:

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

Migden, Michael R ; Rischin, Danny ; Schmults, Chrysalyne D ; Guminski, Alexander ; Hauschild, Axel ; Lewis, Karl D ; Chung, Christine H ; Hernandez-Aya, Leonel ; Lim, Annette M ; Chang, Anne Lynn S ; Rabinowits, Guilherme ; Thai, Alesha A ; Dunn, Lara A ; Hughes, Brett G.M ; Khushalani, Nikhil I ; Modi, Badri ; Schadendorf, Dirk ; Gao, Bo ; Seebach, Frank ; Li, Siyu ; Li, Jingjin ; Mathias, Melissa ; Booth, Jocelyn ; Mohan, Kosalai ; Stankevich, Elizabeth ; Babiker, Hani M ; Brana, Irene ; Gil-Martin, Marta ; Homsi, Jade ; Johnson, Melissa L ; Moreno, Victor ; Niu, Jiaxin ; Owonikoko, Taofeek K ; Papadopoulos, Kyriakos P ; Yancopoulos, George D ; Lowy, Israel ; Fury, Matthew G

The New England journal of medicine, 2018-07, Vol.379 (4), p.341-351 [Periódico revisado por pares]

United States: Massachusetts Medical Society

Texto completo disponível

Citações Citado por

Enviar para

Título:
PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Autor: Migden, Michael R ; Rischin, Danny ; Schmults, Chrysalyne D ; Guminski, Alexander ; Hauschild, Axel ; Lewis, Karl D ; Chung, Christine H ; Hernandez-Aya, Leonel ; Lim, Annette M ; Chang, Anne Lynn S ; Rabinowits, Guilherme ; Thai, Alesha A ; Dunn, Lara A ; Hughes, Brett G.M ; Khushalani, Nikhil I ; Modi, Badri ; Schadendorf, Dirk ; Gao, Bo ; Seebach, Frank ; Li, Siyu ; Li, Jingjin ; Mathias, Melissa ; Booth, Jocelyn ; Mohan, Kosalai ; Stankevich, Elizabeth ; Babiker, Hani M ; Brana, Irene ; Gil-Martin, Marta ; Homsi, Jade ; Johnson, Melissa L ; Moreno, Victor ; Niu, Jiaxin ; Owonikoko, Taofeek K ; Papadopoulos, Kyriakos P ; Yancopoulos, George D ; Lowy, Israel ; Fury, Matthew G
Assuntos: Adult ; Aged ; Aged, 80 and over ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal - therapeutic use ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Body weight ; Cancer therapies ; Carcinoma, Squamous Cell - drug therapy ; Carcinoma, Squamous Cell - pathology ; Carcinoma, Squamous Cell - secondary ; Constipation ; Departments ; Dermatology ; Diarrhea ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug dosages ; Fatigue ; Female ; Health risk assessment ; Hospitals ; Humans ; Immune checkpoint ; Immunosuppression ; Immunotherapy ; Intravenous administration ; Male ; Medicine ; Metastases ; Metastasis ; Middle Aged ; Nausea ; Neoplasm Staging ; Oncology ; Patients ; PD-1 protein ; Programmed Cell Death 1 Receptor - antagonists & inhibitors ; Programmed Cell Death 1 Receptor - immunology ; Response rates ; Skin ; Skin Neoplasms - drug therapy ; Skin Neoplasms - pathology ; Statistical analysis ; Surgery ; Tumors ; Womens health
É parte de: The New England journal of medicine, 2018-07, Vol.379 (4), p.341-351
Descrição: Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was associated with the expected spectrum of adverse events.
Editor: United States: Massachusetts Medical Society
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

United States: Massachusetts Medical Society

Buscando em bases de dados remotas. Favor aguardar.